CN113768930B - Application of glatiramer and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus medicines - Google Patents
Application of glatiramer and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus medicines Download PDFInfo
- Publication number
- CN113768930B CN113768930B CN202111039473.9A CN202111039473A CN113768930B CN 113768930 B CN113768930 B CN 113768930B CN 202111039473 A CN202111039473 A CN 202111039473A CN 113768930 B CN113768930 B CN 113768930B
- Authority
- CN
- China
- Prior art keywords
- glatiramer
- enterovirus
- pharmaceutically acceptable
- effect
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of glatiramer and/or medicinal derivatives thereof in preparation of anti-enterovirus medicaments, and the application proves that the glatiramer has stronger antiviral activity on enteroviruses such as EV71, Coxsackie virus and the like, can obviously inhibit cytopathic effect (CPE) generated by the enteroviruses on host cells RD, and enhances the cell survival rate; can inhibit the replication of viruses and show stronger antiviral effect at the cellular level, and has obvious technical effect. The result of the invention shows that the compound glafenin has potential to prepare specific treatment medicines for resisting enterovirus infection, and has better clinical application prospect.
Description
Technical Field
The invention relates to the technical field of biological medicines, in particular to application of glatiramer and/or medicinal derivatives thereof in preparation of anti-enterovirus medicines.
Background
Enterovirus 71 (Enterovirus, EV71) is a member of the genus Enterovirus of the family Picornaviridae (Picornaviridae) and is a non-enveloped virus, the virion is in the shape of a regular icosahedral sphere with a diameter of about 30nm, the genome of the virion is a single positive RNA strand, the length of the virion is about 7.5kb, and the virion is one of the most main pathogens causing hand-foot-and-mouth disease of infants. Infants with hand-foot-and-mouth are sometimes accompanied by serious central nervous system complications, including aseptic meningitis, encephalitis, poliomyelitis-like paralysis, neurological cardiopulmonary failure, and the like, and even death. Humans are the only natural hosts of enteroviruses, which spread by close contact between humans (through fingers, cutlery and food). The infected person has viruses in the pharynx and the intestine, and the time for expelling the viruses from the feces is long and can last for several weeks. Fecal-oral is the primary route of transmission. Occasionally, it may be transmitted by droplets. The disease is most frequently found in children under 5 years old, and the incidence rate is highest in children under 1-2 years old.
Enterovirus 71 ((Enterovirus, EV 71)) belongs to a member of Enterovirus (Enterovirus) of Picornaviridae (Picornaviridae), is one of the most main pathogens causing infantile hand-foot-and-mouth diseases, sometimes is accompanied by serious central nervous system complications including aseptic meningitis, brainstem encephalitis, autonomic nervous disorders, pulmonary edema and the like, and even causes death. since the first report in 1969, EV71 infectious diseases have been frequently outbreaks and epidemics worldwide, and are severe in Asia-Pacific regions, particularly China at present, viral disease prevention and treatment mainly depend on vaccines and medicaments, related vaccines are marketed in 2015, no specific data can support marketed vaccines to protect enteroviruses of other serotypes at present, treatment methods for EV71 virus infection are quite limited, and main treatment methods are symptomatic support treatment and broad-spectrum antiviral therapy, it has limited curative effect, large individual difference and difficult popularization. Therefore, the research and development of related antiviral drugs can be a key direction for overcoming the virus, and the development of specific and effective anti-EV 71 drugs is imperative.
Therefore, there is a need to develop a new enterovirus infectious disease drug.
Disclosure of Invention
The application finds that the glatiramer has a strong inhibiting effect on enteroviruses for the first time, and provides a direction for treating and preventing enterovirus infectious diseases.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides application of glafenin and/or pharmaceutically acceptable derivatives thereof in preparing an anti-enterovirus medicament.
Further, the enterovirus includes at least one of enterovirus type 71, coxsackievirus type B3 and coxsackievirus type B4.
Further, the pharmaceutically acceptable derivatives of glatiramer include: a pharmaceutically acceptable salt of glatiramer, a pharmaceutically acceptable acid addition salt of glatiramer.
Further, in the pharmaceutically acceptable acid addition salt of glatiramer, the pharmaceutically acceptable acid may be selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulfonic acid, benzenesulfonic acid, and camphoric acid.
Further, the pharmaceutically acceptable salt of glatiramer comprises at least one of an inorganic salt and an organic salt.
Further, the inorganic salt comprises one of hydrochloride, hydrobromide, sulfate, nitrate and phosphate; the organic salt comprises one of mesylate, maleate, tartrate, succinate, acetate, trifluoroacetate, fumarate, citrate, benzene sulfonate, benzoate, benzene sulfonate, lactate and malate. The embodiment of the invention specifically selects hydrochloride of glatiramer.
Furthermore, the anti-enterovirus medicine also comprises pharmaceutically acceptable auxiliary materials and carriers.
Further, the adjuvant includes at least one of a filler, a disintegrant, a binder, an excipient, a diluent, a lubricant, a sweetener, or a coloring agent.
Further, the dosage form of the medicament comprises at least one of granules, tablets, pills, capsules, injections or dispersing agents.
Further, the antiviral means of the drug comprises: inhibit enterovirus intracellular nucleic acid replication, viral protein expression and infection.
One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
the application of the glatiramer and/or the medicinal derivatives thereof in preparing the anti-enterovirus medicaments provided by the invention is that the glatiramer is always used as a compound for targeted treatment of breast cancer, and the new application of the glatiramer in preparing the anti-EV 71 virus medicaments is found for the first time. Test results show that the glatiramer has stronger antiviral activity on enteroviruses such as EV71 and CVB3, can remarkably inhibit cytopathic effect (CPE) generated by the enteroviruses such as EV71 and CVB3 on host cells RD, and enhances the cell survival rate; can inhibit the replication of viruses and show stronger antiviral effect at the cellular level, and has obvious technical effect. The result of the invention shows that the compound glafenin has potential to prepare specific treatment medicines for resisting enterovirus infection, and has better clinical application prospect.
Meanwhile, the synthesis process of the glafenine small molecular compound is simple and is easy for large-scale production and popularization; the antiviral activity of glafenin is not reported, and the glafenin has a certain guiding effect on the development of the activity of resisting enteroviruses such as EV71 and CVB 3; the anti-enterovirus medicine is searched from the compounds with similar structures, the action target of the anti-enterovirus medicine is easy to be found through the structure-activity relationship research, and certain reference significance is provided for further medicine development.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on the drawings without creative efforts.
FIG. 1 is a graph showing the analysis of the results of RD cytotoxicity test of the effect of glatiramer on EV71 virus in example 1 of the present invention;
FIG. 2 is a graph showing the effect of glatiramer in example 2 of the present invention on the cytopathic effect (CPE) produced by EV71 virus in host RD cells;
FIG. 3 is a graph showing the analysis of the results of the measurement of antiviral activity of glatiramer at different concentrations in example 3 of the present invention;
FIG. 4 is a graph showing the analysis of the results of detecting the effect of glatiramer on the propagation of EV71 virus in example 4 of the present invention;
FIG. 5 is a graph showing the analysis of the test results of the effect of glatiramer on EV71 replication in example 5 of the present invention;
FIG. 6 is a graph showing the effect of Gradepin on the replication of CVB4 in example 6 of the present invention.
Detailed Description
The present invention will be specifically explained below in conjunction with specific embodiments and examples, and the advantages and various effects of the present invention will be more clearly presented thereby. It will be understood by those skilled in the art that these specific embodiments and examples are for the purpose of illustrating the invention and are not to be construed as limiting the invention.
Throughout the specification, unless otherwise specifically noted, terms used herein should be understood as having meanings as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is a conflict, the present specification will control.
Unless otherwise specifically stated, various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or can be obtained by an existing method.
In order to solve the technical problems, the general idea of the embodiment of the application is as follows:
the Glafenine (Glafenane) is 2, 3-dihydroxypropyl 2- ((7-chloroquinolin-4-yl) amino) benzoic acid, is a non-narcotic analgesic and a non-steroidal anti-inflammatory drug, is used for treating pain caused by inflammation for a long time and has a good effect.
The structural formula of Glafenine (glafeneine) is as follows:
the inventor of the application combines the virus RNA level analysis, the titer determination and the MTT determination cell survival rate detection method to perform an anti-enterovirus activity research experiment on the glatiramer small molecular compound, and the data analysis in the embodiment adopts Graphpad software to perform statistical analysis, so that the glatiramer has a strong inhibition effect on enteroviruses. The enterovirus includes at least one of enterovirus 71, coxsackievirus B3 and coxsackievirus B4.
Specifically, the method comprises the following steps: glatiramer was evaluated for its inhibitory activity against enteroviruses and tested for activity by standard antiviral activity test methods. A large number of biological experiments show that the glatiramer has good activity of inhibiting replication of enteroviruses, and specifically can inhibit nucleic acid replication and virus protein expression of enterovirus viruses in cells, so that the proliferation of the viruses is inhibited.
Experimental results show that the glatiramer has stronger antiviral activity on the enterovirus 71, can obviously inhibit cytopathic effect (CPE) generated by the enterovirus 71 on a host cell RD, and enhances the cell survival rate; can inhibit replication of enterovirus 71, has strong antiviral effect at cell level, and has obvious technical effect. The glatiramer has stronger antiviral activity on enterovirus 71, shows stronger antiviral effect on the cellular level, and has 100 percent of inhibition rate on the enterovirus when the glatiramer is 20 mu M.
In addition, under different concentration conditions, the glafenin has obvious inhibition effect on the replication of coxsackie virus type 4 (CVB 4).
In conclusion, the result of the invention shows that the compound glafenin has potential to prepare specific treatment medicines for resisting enterovirus infection, and has better clinical application prospect.
Therefore, the invention provides an application of glatiramer in preparing anti-enterovirus medicines, wherein the application refers to that the glatiramer is added with pharmaceutically acceptable auxiliary materials and carriers for preparing anti-enterovirus preparations, the auxiliary materials comprise at least one of filling agents, disintegrating agents, binding agents, excipients, diluents, lubricants, sweetening agents or coloring agents, and different auxiliary materials are selected according to the requirements of the medicine dosage forms. The preparation is granule, tablet, pill, capsule, injection or dispersant.
It can be understood that the glafenin is used as a lead compound for further structural optimization, and the glafenin is used for preparing a medicament for treating enterovirus infectious diseases and also belongs to the protection scope of the invention. Wherein the pharmaceutically acceptable derivatives of glatiramer include pharmaceutically acceptable salts of glatiramer and pharmaceutically acceptable acid addition salts of glatiramer.
The use of glatiramer in the present application for the preparation of anti-enterovirus medicaments will be described in detail below with reference to examples and experimental data.
Example 1 cytotoxicity assay for glatiramer
In RD cells, glatiramer cytotoxicity was examined. RD cells were seeded in 96 wells at 37 ℃ with 5% CO 2 Culturing in an incubator for 12-16h, discarding cell culture solution, adding cell maintenance solution containing glatiramer with different concentrations, culturing, repeating 3 wells for each group, and adding PBS with same amount for control group. After 48h of action, staining with MTT and detecting OD 492 nM, cell viability was analyzed.
And (4) analyzing results: as shown in FIG. 1, the Prism7 software calculates the half-toxic concentration (CC) of the drug to the cell 50 ) CC of Glafeine 50 It was 329310 nM. In the subsequent examples, glatiramer was used at a maximum concentration of 20000nM, within a safe and non-toxic range.
Example 2 detection of antiviral Activity of glatiramer against EV71
RD cells were plated in 96-well cell culture plates at 37 ℃ with 5% CO 2 After the culture in an incubator for 12-16h, 100TCID 50 The EV71 virus liquid infects cells for 2h, cell maintenance liquid containing different concentrations of test glatiramer is added respectively to continue culturing for about 48h, and PBS with the same volume is added as negative control. When the virus control wells showed CPE lesions in about 90%, cytopathic effect (CPE) was observed under a microscope.
And (4) analyzing results: inhibition of RD cell CPE effect by EV71 by glafenin As shown in FIG. 2, RD cells infected with EV71 become round and are separated from cell plate walls, and treatment with different concentrations of test compounds has a significant inhibitory effect on the pathological effect.
Example 3 assay for inhibition of EV71 proliferation Activity by glatiramer
RD cells were seeded in 24-well cell culture plates at 37 ℃ with 5% CO 2 Culturing in incubator for 12-16h with 100TCID 50 2h after infection with EV71 virus solution, treatment was performed with cell maintenance solutions containing varying concentrations of experimental glafenin, and the same volume of PBS was added as the negative control. After 24h of treatment, pass TCID 50 The titer assay measures the effect of inhibiting viral proliferation.
And (4) analyzing results: the detection result is shown in fig. 3, under different concentration conditions, the compound glafenin has a significant inhibition effect on EV71, and the TCID of the virus can be obviously reduced in a drug treatment group compared with a control group 50 Value of (A). The glatiramer has stronger antiviral activity on enteroviruses, shows stronger antiviral effect on a cellular level, and has 100 percent of inhibition rate on EV71 virus at 20 mu M of the glatiramer.
Example 4 Effect of Grafenan on EV71 replication
The experiment detects that glatiramer has better inhibitory activity to EV 71:
RD cells were seeded in 24-well cell culture plates at 37 ℃ with 5% CO 2 Culturing in incubator for 12-16h with 100TCID 50 2h after infection with EV71 virus, treatment was performed with test compound (glafenin) containing different concentrations, and the same volume of PBS was added as the negative control. After 16h of treatment, collecting the cultured cells to extract total RNA, and detecting the effect of the glatiramer on inhibiting virus replication by a real-time fluorescent quantitative PCR (qPCR) method.
And (4) analyzing results: the detection result is shown in fig. 4, which shows the influence of glatiramer on EV71 replication, and glatiramer has a significant inhibitory effect on the expression of VP1 gene of EV71 virus under different concentration conditions.
Example 5 inhibition of EV71 replication by Grafenin
The experiment detects that glatiramer has better inhibitory activity to EV 71:
RD cells were seeded in 24-well cell culture plates at 37 ℃ with 5% CO 2 Culturing in incubator for 12-16h with 100TCID 50 2h after infection with EV71 virus solution, treatment was performed with test compound (glafenin) containing different concentrations, and negative controls were added to the same volume of maintenance solution without drug. After 16h of treatment, total RNA is extracted from the cultured cells, and the expression of the EV71 virus VP1 is detected by a real-time fluorescent quantitative PCR (qPCR) method.
And (4) analyzing results: as shown in FIG. 5, the Prism7 software calculated the half inhibitory Concentration (Concentration for 50% of maximum inhibition, IC) of the drug against viral replication 50 ) IC of glafenine 50 It was 191.1 nM.
Example 6 Effect of Grafenin on replication of CVB4
Inoculating Hela cellsSeeded in 12-well plates at 37 ℃ with 5% CO 2 Culturing in incubator for 12-16h with 100TCID 50 After 2h infection with CVB4 virus solutions, the samples were treated with test compounds (glafenin) at different concentrations, and the negative control was supplemented with the same volume of glafenin-free cell maintenance solution. After 17h of treatment, the effect of the Greenin on inhibiting the CVB4 virus replication is detected by a real-time fluorescent quantitative PCR (qPCR) method.
And (4) analyzing results: the detection result is shown in fig. 6, and under different concentration conditions, glatiramer has a remarkable inhibition effect on the replication of CVB 4.
In conclusion, the glatiramer has remarkable activity of inhibiting EV71 and CVB4 replication, can strongly inhibit RD cytopathic effect caused by EV71 viruses, and enhances the cell survival rate; inhibiting the replication of the viral RNA level and having the potential to further develop and prepare a medicament which is clinically effective against the enterovirus infection.
Finally, it should also be noted that the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (8)
1. Use of glatiramer and/or a pharmaceutically acceptable salt thereof in the manufacture of an anti-enterovirus medicament.
2. The use of claim 1, wherein the enterovirus comprises at least one of enterovirus type 71, coxsackievirus type B3, and coxsackievirus type B4.
3. The use according to claim 1, wherein said pharmaceutically acceptable salt of glatiramer comprises a pharmaceutically acceptable acid addition salt of glatiramer.
4. The use according to claim 3, wherein the pharmaceutically acceptable salt of glatiramer comprises glatiramer hydrochloride.
5. The use of claim 1, wherein the anti-enterovirus medicament further comprises pharmaceutically acceptable excipients and carriers.
6. The use according to claim 5, wherein the adjuvant comprises at least one of a filler, a disintegrant, a binder, an excipient, a diluent, a lubricant, a sweetener, or a coloring agent.
7. The use of claim 1, wherein the dosage form of the anti-enterovirus drug comprises at least one of granules, tablets, pills, capsules, injections or dispersions.
8. The use according to claim 7, wherein the anti-viral means of the anti-enteroviral drug comprises: inhibit enterovirus intracellular nucleic acid replication, viral protein expression and infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111039473.9A CN113768930B (en) | 2021-09-06 | 2021-09-06 | Application of glatiramer and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111039473.9A CN113768930B (en) | 2021-09-06 | 2021-09-06 | Application of glatiramer and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus medicines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113768930A CN113768930A (en) | 2021-12-10 |
| CN113768930B true CN113768930B (en) | 2022-08-23 |
Family
ID=78841078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111039473.9A Active CN113768930B (en) | 2021-09-06 | 2021-09-06 | Application of glatiramer and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113768930B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102440988A (en) * | 2011-12-28 | 2012-05-09 | 武汉大学 | Application of arbidol hydrochloride in preparation of anti-enterovirus medicines |
| CN106668014A (en) * | 2016-12-21 | 2017-05-17 | 湖北工业大学 | Application of nitrogen-containing heterocyclic ring ester compounds to preparation of medicine for resisting coxsackie virus type B3 |
| CN106692143A (en) * | 2016-12-21 | 2017-05-24 | 湖北工业大学 | Application of ester compounds in preparing drugs resistant to coxsackievirus B3 |
-
2021
- 2021-09-06 CN CN202111039473.9A patent/CN113768930B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102440988A (en) * | 2011-12-28 | 2012-05-09 | 武汉大学 | Application of arbidol hydrochloride in preparation of anti-enterovirus medicines |
| CN106668014A (en) * | 2016-12-21 | 2017-05-17 | 湖北工业大学 | Application of nitrogen-containing heterocyclic ring ester compounds to preparation of medicine for resisting coxsackie virus type B3 |
| CN106692143A (en) * | 2016-12-21 | 2017-05-24 | 湖北工业大学 | Application of ester compounds in preparing drugs resistant to coxsackievirus B3 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113768930A (en) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111557939B (en) | Use of favipiravir for the treatment of coronavirus infections | |
| CN113289018B (en) | Application of old medicines such as auranofin and the like and compositions thereof in resisting single positive strand RNA viruses | |
| CN113827596B (en) | Application of lapatinib and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus drugs | |
| CN108721281A (en) | New antiviral drugs and its application | |
| EP4014975A1 (en) | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | |
| CN113082049B (en) | New application of potassium iodide or composition containing potassium iodide in preparation of drugs for treating African swine fever | |
| CN111743899B (en) | Application of nitazoxanide and its active form tizoxanide in preparing medicine for treating SARS-CoV-2 infection | |
| CN113773275A (en) | Antiviral compound and preparation method thereof | |
| CN113768930B (en) | Application of glatiramer and/or pharmaceutically acceptable derivatives thereof in preparation of anti-enterovirus medicines | |
| CN106880630B (en) | Retro-2cyclAnd use of related derivatives | |
| CN115381816A (en) | Application of VER50589 in preparing medicine for resisting enterovirus 71 | |
| CN113827586B (en) | Application of nortriptyline hydrochloride in preparation of anti-enterovirus drugs | |
| CN113288900A (en) | Use of Barosavir or Barosavirate for the production of a medicament for the prophylaxis and/or treatment of diseases caused by novel coronaviruses | |
| CN113768920A (en) | Application of quercetin and/or medicinal derivatives thereof in preparation of anti-enterovirus medicines | |
| CN111317752A (en) | Medicine for preventing or treating influenza virus infection and application | |
| CN115737646B (en) | Use of Mefloquine Hydrochloride in preparation of anti-enterovirus medicine | |
| CN115381828B (en) | Application of pilalaisib in preparation of anti-enterovirus 71 type medicine | |
| CN115869324B (en) | Application of Efavirennz in preparation of anti-enterovirus drugs | |
| CN114306298B (en) | Application of 2,3, 5-triiodo-benzoyl hydrazine in preparing anti-EV 71 virus medicament | |
| CN113633652B (en) | Application of liquiritin in preparing medicament for treating or preventing enterovirus71 type infection | |
| CN114452273B (en) | Application of iodized hydrazide and iodized hydrazide polyacid derivative in preparation of CVB3 virus resistant drugs | |
| CN110179785B (en) | Application of widmanone in preparation of medicine for treating or preventing hand-foot-and-mouth disease | |
| CN114796256B (en) | Application of cyclic adenylate compound in preparation of anti-Zika virus drugs | |
| US20220204501A1 (en) | Enterovirus inhibitor | |
| CN102885841A (en) | Application of punicalagin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |